In a significant development involving the Environmental Protection Agency (EPA) and Bayer, internal records have revealed a meeting between top US regulators and Bayer’s CEO, Bill Anderson. The gathering, held on 17 June 2025, centred on litigation strategies concerning the controversial glyphosate weed killer, which has been linked to cancer allegations from numerous plaintiffs across the United States. This meeting took place just months before the Trump administration initiated actions that could bolster Bayer’s legal position in ongoing court battles.
Meeting Details and Implications
Documents obtained through a Freedom of Information Act request indicate that the gathering at the EPA included key figures such as Lee Zeldin, the agency’s administrator, alongside other senior officials. The meeting’s agenda explicitly noted “supreme court action” as a focal point, suggesting that Bayer intended to seek the EPA’s support in its ongoing legal struggles. The company faces thousands of lawsuits claiming its glyphosate-based herbicides, like Roundup, contributed to cancer diagnoses among users.
The core of Bayer’s legal strategy hinges on the assertion that if the EPA does not mandate a cancer warning for glyphosate products, the company should not bear liability for failing to provide such warnings. This argument has met with mixed responses in the courts; while one appellate court sided with Bayer, others, including the Biden administration’s solicitor general, have dismissed this preemption argument.
Political Support for Bayer
The timing of the meeting raises eyebrows, particularly given the subsequent actions taken by the Trump administration that appeared to favour Bayer. Following the meeting, the administration filed a brief with the Supreme Court advocating for Bayer’s case, and on 18 February 2026, the White House invoked the Defense Production Act, offering protection for glyphosate herbicide production and immunity for manufacturers.
Critics argue that the close relationship between Bayer and the EPA highlights a troubling trend where corporate interests may overshadow public health concerns. Nathan Donley, from the Center for Biological Diversity, expressed alarm over the apparent prioritisation of industry profits over the safety of American citizens.
Corporate Influence on Regulatory Decisions
The implications of this high-level meeting extend beyond legal strategy; they underscore the potential influence of corporate power on regulatory agencies. Legal experts and advocacy groups have voiced their concerns regarding the perceived preferential treatment given to corporate leaders in discussions that should be inclusive of affected communities.
Whitney Di Bona, a consumer safety advocate, questioned whether individuals harmed by glyphosate had an opportunity to voice their concerns to the EPA. This sentiment was echoed by Naomi Oreskes, a Harvard professor, who noted that the access industry leaders enjoy often contrasts sharply with the barriers faced by ordinary citizens seeking to engage with regulatory bodies.
Zen Honeycutt, founder of Moms Across America, expressed frustration at the lack of meaningful engagement from the EPA regarding community concerns about pesticide safety. The imbalance in access to regulatory discussions raises critical questions about whose voices are being heard in policy-making processes.
Why it Matters
The revelations surrounding the EPA’s meeting with Bayer’s CEO highlight the precarious intersection of corporate influence and public health policy. As ongoing litigation surrounding glyphosate continues to unfold, the actions of regulatory agencies will likely play a pivotal role in shaping the landscape of agricultural chemicals and the accountability of major corporations. The potential ramifications for public health, environmental safety, and corporate regulation are profound, underscoring the necessity for transparency and equitable access in discussions that affect millions of lives.
